読み込み中
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
前日終値
$3.32
+$0.12 · +3.75%
日中の時刻はETです。市場データは遅延する場合があります。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日中レンジ
現在 $3.32
52週レンジ
現在 $3.32
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
57
適正価値
センチメント
44
まちまち
リスク
69
高リスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日中レンジ
現在 $3.32
52週レンジ
現在 $3.32
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 70.59万 USD | 46.43万 USD | 22.62万 USD | 25.54万 USD | 72.27万 USD |
| 売上原価 | 2720 USD | 4822 USD | 3.15万 USD | 7.18万 USD | 17.53万 USD |
| 粗利益 | 70.32万 USD | 45.95万 USD | 19.47万 USD | 18.36万 USD | 54.74万 USD |
| 研究開発 | 823.88万 USD | 236.06万 USD | 366.67万 USD | 184.27万 USD | 126.29万 USD |
| 販売・一般管理 | 434.52万 USD | 385.2万 USD | 306.2万 USD | 495.99万 USD | 497.13万 USD |
| 営業費用 | 1258.39万 USD | 621.26万 USD | 672.87万 USD | 680.26万 USD | 623.42万 USD |
| 受取利息 | 3017 USD | 1.43万 USD | 4.32万 USD | — | — |
| 減価償却費と償却費 | 8.78万 USD | 7.62万 USD | 14.54万 USD | 10.27万 USD | 14.76万 USD |
| 営業利益 | −1188.07万 USD | −575.31万 USD | −653.4万 USD | −661.9万 USD | −568.69万 USD |
| 純利益 | −1190.18万 USD | −579.53万 USD | −666.49万 USD | −726.93万 USD | −402.7万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$1.50
下落余地（54.82%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年8月3日 | 1:15 | — | — |
株式分割 | 2021年1月12日 | 1:30 | — | — |
株式分割 | 2015年12月16日 | 11:10 | — | — |
株式分割 | 2009年6月30日 | 1:4 | — | — |
発効済み 2026年8月3日
1:15
発効済み 2021年1月12日
1:30
発効済み 2015年12月16日
11:10
発効済み 2009年6月30日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
